Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO2011047173) PHARMACEUTICAL COMPOSITIONS FOR ORAL ADMINISTRATION
Note: Text based on automatic Optical Character Recognition processes. Please use the PDF version for legal matters

WHAT IS CLAIMED IS

1. A pharmaceutical composition for oral administration to a mammal comprising one or more pharmaceutically acceptable excipients and a therapeutically effective amount of a spiro-oxindole compound having the following formula (I):


as a racemate, a single enantiomer, or a non-racemic mixture of enantiomers, or a pharmaceutically acceptable salt thereof.

2. The pharmaceutical composition of Claim 1 comprising two or more pharmaceutically acceptable excipients.

3. The pharmaceutical composition of Claim 2 wherein the

pharmaceutically acceptable excipients are selected from the group consisting of Miglyol® 840, Labrafac®, Captex® 200P, Myvacet® 9-45K, PEG 400, Capmul® PG8, TPGS, Neobee® M-5, Transcutol®, Capryol® 90, Solutol® HS 15, Corn Oil Labrasol®, Capryol® 90, Gelucire® 44/14, a cyclodextrin, PEG 400, PEG 6000, ethanol, water, propylene glycol, Cremophor ELP®, Imwitor® 742, Vitamin E and Polyvinylpyrrolidone (PVP).

4. The pharmaceutical composition of Claim 3 wherein the

pharmaceutically acceptable excipients are selected from the group consisting of Labrasol®, Gelucire® 44/14 and propylene glycol.

5. The pharmaceutical composition of Claim 3 wherein the

pharmaceutically acceptable excipients are selected from the group consisting of Labrasol®, Cremophor® ELP, Imwitor® 742, Vitamin E and PVP.

6. The pharmaceutical composition of Claim 4 wherein each

pharmaceutically acceptable excipient is present in a concentration of from about 0.1% w/w to about 99% w/w.

7. The pharmaceutical composition of Claim 6 wherein Labrasol® is present in a concentration of from about 30% to about 70% w/w, Gelucire® 44/14 is present in a concentration of from about 20% to about 50% w/w and propylene glycol is present in a concentration of from about 0.5% to about 20% w/w.

8. The pharmaceutical composition of Claim 7 wherein Labrasol® is present in a concentration of from about 35% to about 65% w/w, Gelucire® 44/14 is present in a concentration of from about 25% to about 45% w/w and propylene glycol is present in a concentration of from about 1.0% to about 10% w/w.

9. The pharmaceutical composition of Claim 5 wherein each

pharmaceutically acceptable excipient is present in a concentration of from about 0.1% w/w to about 99% w/w.

10. The pharmaceutical composition of Claim 9 wherein Labrasol® is present in a concentration of from about 30% to about 70% w/w, Cremophor ELP® is present in a concentration of from about 20% to about 50% w/w, Imwitor® 742 is present in a concentration of from about 0.5% to about 10% w/w, Vitamin E is present in a concentration of from about 0.1% to about 5% w/w and PVP is present in a concentration of from about 0.5% to about 10% w/w.

11. The pharmaceutical composition of any one of Claims 1-10 wherein the spiro-oxoindole compound is present in a concentration of from about 0.1% w/w to about 25% w/w.

12. The pharmaceutical composition of any one of Claims 1 -10 in a capsule form containing the spiro-oxindole compound in a unit dosage amount of between about 5 mg to about 100 mg.

13. The pharmaceutical composition of any one of Claims 1-10 wherein the pharmaceutical composition is in liquid form.

14. A pharmaceutical composition for oral administration to a mammal comprising one or more pharmaceutically acceptable excipients and a therapeutically effective amount of a spiro-oxindole compound having the following formula (I):


as a racemate, a single enantiomer, or a non-racemic mixture of enantiomers, or a pharmaceutically acceptable salt thereof;

wherein the spiro-oxindole compound is present in a concentration of from about 0.1 % w/w to about 25% w/w, wherein a first pharmaceutically acceptable excipient is Labrasol® and is present in a concentration of from about 35% w/w to about 65% w/w, wherein a second pharmaceutically acceptable excipient is Gelucire® 44/1 and is present in a concentration of from about 25% w/w to about 45% w/w, and wherein a third pharmaceutically acceptable excipient is propylene glycol and is present in a concentration of from about 1.0% w/w to about 10% w/w.

15. A pharmaceutical composition for oral administration to a mammal comprising one or more pharmaceutically acceptable excipients and a therapeutically effective amount of a spiro-oxindole compound having the following formula (I):


as a racemate, a single enantiomer, or a non-racemic mixture of enantiomers, or a pharmaceutically acceptable salt thereof;

wherein the spiro-oxindole compound is present in an unit dosage amount of between about 5 mg and about 100 mg, wherein a first pharmaceutically acceptable excipient is Labrasol® and is present in a concentration of from about 35% w/w to about 65% w/w, wherein a second pharmaceutically acceptable excipient is Gelucire® 44/14 and is present in a concentration of from about 25% w/w to about 45% w/w, and wherein a third pharmaceutically acceptable excipient is propylene glycol and is present in a concentration of from about 1.0% w/w to about 10% w/w.

16. The pharmaceutical composition of any one of Claims 1-15 wherein the spiro-oxindole compound is the (S)-enantiomer of the compound of formula (I) having the following formula (l-S):


17. A method of treating a sodium channel-mediated disease or condition in a mammal, wherein the method comprises orally administering to the mammal in need thereof a therapeutically effective amount of a pharmaceutical composition comprising one or more pharmaceutically acceptable excipients and a therapeutically effective amount of a spiro-oxindole compound having the following formula (I):


as a racemate, a single enantiomer, or a non-racemic mixture of enantiomers, or a pharmaceutically acceptable salt thereof.

18. The method of Claim 17, wherein said disease or condition is selected from the group consisting of pain associated with HIV, HIV treatment induced neuropathy, trigeminal neuralgia, post-herpetic neuralgia, diabetic neuropathy, peripheral neuropathy, Complex regional pain syndrome, Paroxysmal Extreme Pain

Disorder, eudynia, familial erythromelalgia, secondary erythromelalgia,

primary/inherited erythromelalgia, familial rectal pain, familial facial pain, dental pain, migraine, headache, familial hemiplegic migraine, sinus headache, tension headache, phantom limb pain, peripheral nerve injury, pain associated with multiple sclerosis (MS); myasthenia syndromes, myotonia, paroxysmal dystonia, periodic paralysis, spasticity, spastic paraplegia, myopathies, paramyotonia congentia, hyperkalemic periodic paralysis, hypokalemic periodic paralysis, malignant hyperthermia, heat sensitivity, irritable bowel syndrome, Crohns disease, motor impairment associated with MS, amyotrophic lateral sclerosis (ALS), pruritis, benign prostatic hyperplasia, arthritis, rheumatoid arthritis, osteoarthritis, cystic fibrosis, pseudoaldosteronism, rhabdomyolysis, bipolar depression, anxiety, schizophrenia, illness due to exposure to insecticides or other sodium channel toxins, cancer, epilepsy, partial and general tonic seizures, restless leg syndrome, fibromyalgia, neuroprotection under ischaemic conditions caused by stroke, glaucoma or neural trauma, arrhythmias, long-QT syndrome, Catecholeminergic polymorphic ventricular tachycardia, tachy-arrhythmias, atrial fibrillation and ventricular fibrillation.

19. The method of Claim 18, wherein said disease or condition is primary/inherited erythromelalgia.

20. The method of Claim 18 wherein the disease or condition is postherpetic neuralgia.

21. A method of treating pain through inhibition of ion flux through a voltage-dependent sodium channel in a mammal, wherein the method comprises orally administering to the mammal in need thereof a therapeutically effective amount of a pharmaceutical composition comprising one or more pharmaceutically acceptable excipients and a therapeutically effective amount of a spiro-oxindole compound having the following formula (I):

as a racemate, a single enantiomer, or a non-racemic mixture of enantiomers, or a pharmaceutically acceptable salt thereof.

22. A method of treating benign prostatic hyperplasia in a mammal, wherein the method comprises orally administering to the mammal in need thereof a therapeutically effective amount of a pharmaceutical composition comprising one or more pharmaceutically acceptable excipients and a therapeutically effective amount of a spiro-oxindole compound having the following formula (I):


as a racemate, a single enantiomer, or a non-racemic mixture of enantiomers, or a pharmaceutically acceptable salt thereof.

23. A method of treating pruritis in a mammal, wherein the method comprises orally administering to the mammal in need thereof a therapeutically effective amount of a pharmaceutical composition comprising one or more

pharmaceutically acceptable excipients and a therapeutically effective amount of a spiro-oxindole compound having the following formula (I):


as a racemate, a single enantiomer, or a non-racemic mixture of enantiomers, or a pharmaceutically acceptable salt thereof.

24. A method of treating cancer in a mammal, wherein the methods comprises orally administering to the mammal in need thereof a therapeutically effective amount of a pharmaceutical composition comprising one or more

pharmaceutically acceptable excipients and a therapeutically effective amount of a spiro-oxindole compound having the following formula (I):


as a racemate, a single enantiomer, or a non-racemic mixture of enantiomers, or a pharmaceutically acceptable salt thereof.

25. The method of any one of Claims 17-24 wherein the spiro-oxindole compound is the (S)-enantiomer of the compound of formula (I) having the following formula (l-S):


or a pharmaceutically acceptable salt thereof.

WHAT IS CLAIMED IS

1. A pharmaceutical composition for oral administration to a mammal comprising one or more pharmaceutically acceptable excipients and a therapeutically effective amount of a spiro-oxindole compound having the following formula (I):


as a racemate, a single enantiomer, or a non-racemic mixture of enantiomers, or a pharmaceutically acceptable salt thereof.

2. The pharmaceutical composition of Claim 1 comprising two or more pharmaceutically acceptable excipients.

3. The pharmaceutical composition of Claim 2 wherein the

pharmaceutically acceptable excipients are selected from the group consisting of Miglyol® 840, Labrafac®, Captex® 200P, Myvacet® 9-45K, PEG 400, Capmul® PG8, TPGS, Neobee® M-5, Transcutol®, Capryol® 90, Solutol® HS 15, Corn Oil Labrasol®, Capryol® 90, Gelucire® 44/14, a cyclodextrin, PEG 400, PEG 6000, ethanol, water, propylene glycol, Cremophor ELP®, Imwitor® 742, Vitamin E and Polyvinylpyrrolidone (PVP).

4. The pharmaceutical composition of Claim 3 wherein the

pharmaceutically acceptable excipients are selected from the group consisting of Labrasol®, Gelucire® 44/14 and propylene glycol.

5. The pharmaceutical composition of Claim 3 wherein the

pharmaceutically acceptable excipients are selected from the group consisting of Labrasol®, Cremophor® ELP, Imwitor® 742, Vitamin E and PVP.

6. The pharmaceutical composition of Claim 4 wherein each

pharmaceutically acceptable excipient is present in a concentration of from about 0.1% w/w to about 99% w/w.

7. The pharmaceutical composition of Claim 6 wherein Labrasol® is present in a concentration of from about 30% to about 70% w/w, Gelucire® 44/14 is present in a concentration of from about 20% to about 50% w/w and propylene glycol is present in a concentration of from about 0.5% to about 20% w/w.

8. The pharmaceutical composition of Claim 7 wherein Labrasol® is present in a concentration of from about 35% to about 65% w/w, Gelucire® 44/14 is present in a concentration of from about 25% to about 45% w/w and propylene glycol is present in a concentration of from about 1.0% to about 10% w/w.

9. The pharmaceutical composition of Claim 5 wherein each

pharmaceutically acceptable excipient is present in a concentration of from about 0.1% w/w to about 99% w/w.

10. The pharmaceutical composition of Claim 9 wherein Labrasol® is present in a concentration of from about 30% to about 70% w/w, Cremophor ELP® is present in a concentration of from about 20% to about 50% w/w, Imwitor® 742 is present in a concentration of from about 0.5% to about 10% w/w, Vitamin E is present in a concentration of from about 0.1 % to about 5% w/w and PVP is present in a concentration of from about 0.5% to about 10% w/w.

11. The pharmaceutical composition of any one of Claims 1-10 wherein the spiro-oxoindole compound is present in a concentration of from about 0.1% w/w to about 25% w/w.

12. The pharmaceutical composition of any one of Claims 1-10 in a capsule form containing the spiro-oxindole compound in a unit dosage amount of between about 5 mg to about 100 mg.

13. The pharmaceutical composition of any one of Claims 1-10 wherein the pharmaceutical composition is in liquid form.

14. A pharmaceutical composition for oral administration to a mammal comprising one or more pharmaceutically acceptable excipients and a therapeutically effective amount of a spiro-oxindole compound having the following formula (I):


as a racemate, a single enantiomer, or a non-racemic mixture of enantiomers, or a pharmaceutically acceptable salt thereof;

wherein the spiro-oxindole compound is present in a concentration of from about 0.1% w/w to about 25% w/w, wherein a first pharmaceutically acceptable excipient is Labrasol® and is present in a concentration of from about 35% w/w to about 65% w/w, wherein a second pharmaceutically acceptable excipient is Gelucire® 44/14 and is present in a concentration of from about 25% w/w to about 45% w/w, and wherein a third pharmaceutically acceptable excipient is propylene glycol and is present in a concentration of from about 1.0% w/w to about 10% w/w.

15. A pharmaceutical composition for oral administration to a mammal comprising one or more pharmaceutically acceptable excipients and a therapeutically effective amount of a spiro-oxindole compound having the following formula (I):


as a racemate, a single enantiomer, or a non-racemic mixture of enantiomers, or a pharmaceutically acceptable salt thereof;

wherein the spiro-oxindole compound is present in an unit dosage amount of between about 5 mg and about 100 mg, wherein a first pharmaceutically acceptable excipient is Labrasol® and is present in a concentration of from about 35% w/w to about 65% w/w, wherein a second pharmaceutically acceptable excipient is Gelucire® 44/14 and is present in a concentration of from about 25% w/w to about 45% w/w, and wherein a third pharmaceutically acceptable excipient is propylene glycol and is present in a concentration of from about 1.0% w/w to about 10% w/w.

16. The pharmaceutical composition of any one of Claims 1-15 wherein the spiro-oxindole compound is the (S)-enantiomer of the compound of formula (I) having the following formula (l-S):


17. A method of treating a sodium channel-mediated disease or condition in a mammal, wherein the method comprises orally administering to the mammal in need thereof a therapeutically effective amount of a pharmaceutical composition comprising one or more pharmaceutically acceptable excipients and a therapeutically effective amount of a spiro-oxindole compound having the following formula (I):


as a racemate, a single enantiomer, or a non-racemic mixture of enantiomers, or a pharmaceutically acceptable salt thereof.

18. The method of Claim 17, wherein said disease or condition is selected from the group consisting of pain associated with HIV, HIV treatment induced neuropathy, trigeminal neuralgia, post-herpetic neuralgia, diabetic neuropathy, peripheral neuropathy, Complex regional pain syndrome, Paroxysmal Extreme Pain

Disorder, eudynia, familial erythromelalgia, secondary erythromelalgia,

primary/inherited erythromelalgia, familial rectal pain, familial facial pain, dental pain, migraine, headache, familial hemiplegic migraine, sinus headache, tension headache, phantom limb pain, peripheral nerve injury, pain associated with multiple sclerosis (MS); myasthenia syndromes, myotonia, paroxysmal dystonia, periodic paralysis, spasticity, spastic paraplegia, myopathies, paramyotonia congentia, hyperkalemic periodic paralysis, hypokalemic periodic paralysis, malignant hyperthermia, heat sensitivity, irritable bowel syndrome, Crohns disease, motor impairment associated with MS, amyotrophic lateral sclerosis (ALS), pruritis, benign prostatic hyperplasia, arthritis, rheumatoid arthritis, osteoarthritis, cystic fibrosis, pseudoaldosteronism, rhabdomyolysis, bipolar depression, anxiety, schizophrenia, illness due to exposure to insecticides or other sodium channel toxins, cancer, epilepsy, partial and general tonic seizures, restless leg syndrome, fibromyalgia, neuroprotection under ischaemic conditions caused by stroke, glaucoma or neural trauma, arrhythmias, long-QT syndrome, Catecholeminergic polymorphic ventricular tachycardia, tachy-arrhythmias, atrial fibrillation and ventricular fibrillation.

19. The method of Claim 18, wherein said disease or condition is primary/inherited erythromelalgia.

20. The method of Claim 18 wherein the disease or condition is postherpetic neuralgia.

21. A method of treating pain through inhibition of ion flux through a voltage-dependent sodium channel in a mammal, wherein the method comprises orally administering to the mammal in need thereof a therapeutically effective amount of a pharmaceutical composition comprising one or more pharmaceutically acceptable excipients and a therapeutically effective amount of a spiro-oxindole compound having the following formula (I):

as a racemate, a single enantiomer, or a non-racemic mixture of enantiomers, or a pharmaceutically acceptable salt thereof.

22. A method of treating benign prostatic hyperplasia in a mammal, wherein the method comprises orally administering to the mammal in need thereof a therapeutically effective amount of a pharmaceutical composition comprising one or more pharmaceutically acceptable excipients and a therapeutically effective amount of a spiro-oxindole compound having the following formula (I):


as a racemate, a single enantiomer, or a non-racemic mixture of enantiomers, or a pharmaceutically acceptable salt thereof.

23. A method of treating pruritis in a mammal, wherein the method comprises orally administering to the mammal in need thereof a therapeutically effective amount of a pharmaceutical composition comprising one or more

pharmaceutically acceptable excipients and a therapeutically effective amount of a spiro-oxindole compound having the following formula (I):


as a racemate, a single enantiomer, or a non-racemic mixture of enantiomers, or a pharmaceutically acceptable salt thereof.

24. A method of treating cancer in a mammal, wherein the methods comprises orally administering to the mammal in need thereof a therapeutically effective amount of a pharmaceutical composition comprising one or more

pharmaceutically acceptable excipients and a therapeutically effective amount of a spiro-oxindole compound having the following formula (I):


as a racemate, a single enantiomer, or a non-racemic mixture of enantiomers, or a pharmaceutically acceptable salt thereof.

25. The method of any one of Claims 17-24 wherein the spiro-oxindole compound is the (S)-enantiomer of the compound of formula (I) having the following formula (l-S):


or a pharmaceutically acceptable salt thereof.